Perlmutter Cancer Center

NYU Langone Health Presentations at ASCO
May 31, 2026

Session: Melanoma/Skin Cancers
Title: Intismeran autogene to induce de novo neoantigen-specific T cells as adjuvant therapy in melanoma.
Senior Author: Janice Mehnert, MD
Time: 9:00AM-12:00PM
Location: Hall A - Posters and Exhibits
Abstract Number: 9564

Session: Lung Cancer—Non-Small Cell Metastatic
Title: ALPACCA: Phase 3 trial of firmonertinib vs investigator's choice of EGFR inhibitor as first-line treatment for locally advanced or metastatic NSCLC with EGFR P-loop and alpha c-helix compressing (PACC) uncommon mutations (FURMO-006)
Co-Author: Elaine Shum, MD
Time: 9:00AM-12:00PM
Location: Hall A - Posters and Exhibits
Abstract Number: TPS8675

Session: Lung Cancer—Non-Small Cell Metastatic
Title: Initial safety and efficacy of A2B694, a logic-gated mesothelin (MSLN)–targeted Tmod chimeric antigen receptor T-cell (CAR T) therapy in patients with advanced solid tumors with HLA-A*02 loss of heterozygosity (LOH)
Senior Author: Salman Punekar, MD
Time: 9:00AM-12:00PM
Location: Hall A - Posters and Exhibits
Abstract Number: 8579

Session: Lung Cancer—Non-Small Cell Metastatic
Title: FF-10832 liposomal gemcitabine monotherapy or combination with pembrolizumab in patients with advanced non–small cell lung cancer
Co-Author: Salman Punekar, MD
Time: 9:00AM-12:00PM

Location: Hall A - Posters and Exhibits
Abstract Number: 8560

Session: Lung Cancer—Non-Small Cell Metastatic
Title: COPERNICUS, a pragmatic phase 2b study of first-line (1L) subcutaneous (SC) amivantamab (ami) + lazertinib (laz) with supportive care in EGFR-mutated advanced NSCLC: Early safety results
Co-Author: Joshua K. Sabari, MD
Time: 9:00AM-12:00PM
Location: Hall A - Posters and Exhibits
Abstract Number: 8613

Session: Lung Cancer—Non-Small Cell Metastatic
Title: COPERNICUS, a pragmatic phase 2b study of subcutaneous (SC) amivantamab (ami) + chemotherapy (chemo) with enhanced dermatologic adverse event (AE) prophylaxis in EGFR-mutated advanced NSCLC: Interim results
Co-Author: Joshua K. Sabari, MD
Time: 9:00AM-12:00PM
Location: Hall A - Posters and Exhibits
Abstract Number: 8614

Session: Lung Cancer—Non-Small Cell Metastatic
Title: PRO results from the Beamion LUNG-1 trial in treatment-naïve patients with HER2-mutant advanced NSCLC
Co-Author: Joshua K. Sabari, MD
Time: 9:00AM-12:00PM
Location: Hall A - Posters and Exhibits
Abstract Number: 8616

Session: Lung Cancer—Non–Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Title: Beamion LUNG-3: Zongertinib in resectable HER2-mutant NSCLC
Co-Author: Elaine Shum, MD
Time: 9:00AM-12:00PM
Location: Hall A - Posters and Exhibits
Abstract Number: TPS8129

Session: Genitourinary Cancer—Prostate, Testicular, and Penile
Title: Dissecting metastatic castration-resistant prostate cancer using regulatory network analysis of tumor transcriptomes
First Author: Aaron Griffin, MD

Senior Author: David Wise, MD
Time: 9:00AM-12:00PM
Location: Hall A - Posters and Exhibits
Abstract Number: 5074

Session: Lung Cancer - Non-Small Cell Metastatic
Title: Efficacy, safety, and cytokine profiling with addition of the toll-like receptor (TLR) 7/8 dual agonist EIK1001 to standard of care (SOC) first-line (1L) therapy: The phase 2 TeLuRide-005 trial in stage 4 NSCLC.
Co-Author: Marissa Rybstein, MD
Time: 9:00AM-12:00PM
Location: Hall A - Posters and Exhibits
Abstract Number: 8568

Session: Lung Cancer - Non-Small Cell Metastatic
Title: A phase 2/3 study of EIK1001 in combination with pembrolizumab and chemotherapy in participants with stage 4 non–small cell lung cancer (NSCLC) (TeLuRide-008)
Co-Author: Marissa Rybstein, MD
Time: 9:00AM-12:00PM
Location: Hall A - Posters and Exhibits
Abstract Number: TPS8668

Session: Lung Cancer - Non-small cell local-regional/small cell/other thoracic cancers
Title: Trends in Income-related lung cancer disparities since the introduction of the USPSTF Screening Guidelines
First Author: Tyler Healy, MD
Senior Author: Daniel Becker, MD
Time: 9:00AM-12:00PM
Location: Hall A - Posters and Exhibits
Abstract Number: 8072

Session: Genitourinary Cancer—Kidney and Bladder
Title: Assessing responses to UGN-102 across EORTC recurrence score groups in patients with recurrent low-grade intermediate-risk NMIBC (ENVISION trial)
Co-Author: William Huang, MD
Time: 9:00AM-12:00PM
Location: Hall A - Posters and Exhibits
Abstract Number: 4601

Session: Head and Neck Cancer
Title: A phase 2 study of ipatasertib in combination with pembrolizumab for first-line treatment

of recurrent or metastatic squamous cell cancer of the head and neck
Co-Author: Zujun Li, MD
Time: 10:00-10:12AM
Location: S100a
Abstract Number: 6006

Session: Hematologic Malignancies—Plasma Cell Dyscrasia
Title: Daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in patients (pts) with newly diagnosed multiple myeloma (NDMM): Final analysis of transplant-ineligible (TIE) pts in the phase 3 CEPHEUS study
Co-Author: Marc Braunstein, MD
Time: 10:21-10:27AM
Location: E450a
Abstract Number: 7513

Session: Plenary Session
Title: Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Primary and final analysis from the phase 3 RASolute 302 study
Co-Author: Paul Oberstein, MD
Time: 3:21-3:33PM
Location: Hall B1
Abstract Number: LBA5